Zepbound

Zepbound is a weight-loss medication that entered the US market in 2023 and is manufactured by Eli Lilly. It's newsworthy due to the surging demand for GLP-1 drugs for weight loss, with approximately 1 in 8 US adults now using such medications. Zepbound's high cost, exceeding $1,000 per month, presents a significant barrier for many individuals, forcing some to make lifestyle sacrifices to afford it. The drug's relevance is further highlighted by the competitive landscape of the weight-loss drug market, where companies like Novo Nordisk (makers of Wegovy and Ozempic) are facing setbacks with their new treatments. The increasing popularity of GLP-1 drugs like Zepbound underscores the growing interest in pharmaceutical interventions for weight management, even as healthy habits remain crucial.